Across TCGA pan-cancer cohorts, GAGE2E Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GAGE2E data layer compared with 9 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher GAGE2E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GAGE2E expression acts as an unfavorable survival marker.
LGG are the cancer types where GAGE2E Mutation most reproducibly stratifies survival.